Gene therapy represents a major step forward for people living with Duchenne muscular dystrophy (DMD), but it also comes with serious risks and unanswered questions, according to the recent publication of guidelines in Neuromuscular Disorders. To help families and doctors navigate this new treatment, the Muscular Dystrophy Association (MDA) and Parent Project Muscular Dystrophy (PPMD) coordinated a set of consensus guidelines focused on safety, patient selection and monitoring.
The Food and Drug Administration approved the first gene therapy for DMD in 2023, and additional therapies are under development. Experts agree that clear standards are essential to make sure patients who qualify can access treatment safely and consistently across different care centers. The recommendations highlight the importance of experienced multidisciplinary teams and real-time safety checks in the first three months after infusion, when complications are most likely.
“These guidelines address institutional readiness, patient selection and eligibility, pre-dosing activities, dosing day procedures, immediate post-infusion monitoring (for the first three months), and long-term follow-up,” explained the guidelines’ authors.
For families, this means doctors will work closely with cardiologists, neurologists and other specialists before recommending gene therapy. Patients undergo a full evaluation to establish a baseline of strength and mobility, which helps doctors track whether the therapy is working and catch problems early. These guidelines also call for careful planning to manage possible side effects, which can be life-threatening if not addressed quickly.
Read more about therapies for DMD
While these guidelines provide a roadmap, researchers acknowledge that many questions remain. Scientists still do not fully understand how long the treatment lasts, when it is best to start or how a patient’s genetic background might affect results. Combination therapies may offer more benefits in the future, but more research and real-world data are needed.
These newly published guidelines also stress fairness in access, noting that language barriers, financial concerns and travel distance can prevent some patients from receiving care. MDA and PPMD encourage families to connect with their networks, including the MDA Resource Center and PPMD’s Gene Therapy Hub, to find information and support.
For patients and caregivers, the message is both hopeful and cautious. Gene therapy may change the course of DMD, but safe delivery requires specialized expertise, ongoing monitoring and collaboration between families and care teams. These guidelines offer families a clearer path forward while the medical community continues working to close knowledge gaps and improve care.
Sign up here to get the latest news, perspectives, and information about DMD sent directly to your inbox. Registration is free and only takes a minute.
